Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PRO1184 |
Synonyms | |
Therapy Description |
PRO1184 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting FOLR1 linked to exatecan, which potentially inhibits growth of FOLR1-expressing tumors (Cancer Res 2022;82(12_Suppl):Abstract nr 1085). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PRO1184 | PRO-1184|PRO 1184 | FOLR1-targeted Therapy 24 | PRO1184 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting FOLR1 linked to exatecan, which potentially inhibits growth of FOLR1-expressing tumors (Cancer Res 2022;82(12_Suppl):Abstract nr 1085). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05579366 | Phase Ib/II | PRO1184 | PRO1184 for Advanced Solid Tumors (PRO1184-001) | Recruiting | USA | 1 |